Apeiron Therapeutics
Apeiron Therapeutics is a clinical-stage biopharmaceutical company focused on developing biomarker-driven therapeutics for cancer. They leverage structure-based, AI-driven drug design to create best-in-class and first-in-class small molecule therapies. Their approach integrates cutting-edge artificial intelligence with deep expertise in drug discovery to advance a pipeline of targeted cancer treatments addressing unmet medical needs. Their lead program, GTA182, is a PRMT5 inhibitor currently in Phase 1 clinical trials for advanced MTAP-null solid tumors.
Apeiron Therapeutics
Apeiron Therapeutics is a clinical-stage biopharmaceutical company focused on developing biomarker-driven therapeutics for cancer. They leverage structure-based, AI-driven drug design to create best-in-class and first-in-class small molecule therapies. Their approach integrates cutting-edge artificial intelligence with deep expertise in drug discovery to advance a pipeline of targeted cancer treatments addressing unmet medical needs. Their lead program, GTA182, is a PRMT5 inhibitor currently in Phase 1 clinical trials for advanced MTAP-null solid tumors.